Effects of Second-generation Antipsychotics on Selected Markers of One-carbon Metabolism and Metabolic Syndrome Components in First-episode Schizophrenia Patients

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2014 Oct 9

PMID 25291992

Citations 15

Authors

Blazej Misiak

Dorota Frydecka

Lukasz Laczmanski

Ryszard Slezak

Andrzej Kiejna

Affiliations

Soon will be listed here.

Abstract

Purpose: Alterations in one-carbon metabolism (OCM) have been repeatedly reported in schizophrenia. However, there is a scarcity of studies addressing the effects of antipsychotics on selected OCM markers in schizophrenia and provided results are inconsistent.

Methods: We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy.

Results: After 12 weeks of treatment, all patients had significantly higher body mass index (BMI), serum levels of total cholesterol (TC), low-density lipoproteins (LDL), triglycerides (TG) and tHcy together with significantly lower levels of folate and vitamin B12. The analysis of differences between SGA revealed the same biochemical alterations in patients treated with olanzapine as in the whole group, while those receiving risperidone had no statistically significant changes in serum folate, vitamin B12 and TG. There was a significantly higher increase in BMI and TC in patients treated with olanzapine in comparison with those treated with risperidone. Patients receiving olanzapine had a higher decrease in vitamin B12 than those assigned to the treatment with risperidone. Changes in folate, vitamin B12, tHcy and TC levels were significant only in males, even after Bonferroni correction. Multiple regression analysis revealed that changes in tHcy levels are associated with gender and baseline metabolic parameters (BMI, glucose, TC, LDL and HDL) but not with selected SGA.

Conclusions: These results indicate that SGA may influence OCM, especially in first-episode schizophrenia (FES) males.

Citing Articles

Low utility of serum folic acid blood tests in healthy children and adolescents, a nationwide cohort.

Vinker-Shuster M, Nakar-Weinstein A, Topf-Olivestone C, Raved D, Golan-Cohen A, Merzon E Eur J Pediatr. 2024; 183(12):5173-5179.

PMID: 39327305 DOI: 10.1007/s00431-024-05798-8.

Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers.

Fuentes-Claramonte P, Estrade A, Solanes A, Ramella-Cravaro V, Garcia-Leon M, de Diego-Adelino J Schizophr Bull Open. 2024; 5(1):sgae018.

PMID: 39228676 PMC: 11369642. DOI: 10.1093/schizbullopen/sgae018.

Association of homocysteine with white matter dysconnectivity in schizophrenia.

Tabata K, Son S, Miyata J, Toriumi K, Miyashita M, Suzuki K Schizophrenia (Heidelb). 2024; 10(1):39.

PMID: 38509166 PMC: 10954654. DOI: 10.1038/s41537-024-00458-0.

Abnormalities in one-carbon metabolism in young patients with psychosis.

Frajerman A, Urban M, Rivollier F, Plaze M, Chaumette B, Krebs M Front Psychiatry. 2023; 14:1128890.

PMID: 36816414 PMC: 9928860. DOI: 10.3389/fpsyt.2023.1128890.

Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.

Rikhari P, Kumar A, Agrawal P, Kumar H J Family Med Prim Care. 2022; 11(5):2194-2200.

PMID: 35800481 PMC: 9254779. DOI: 10.4103/jfmpc.jfmpc_2161_21.

References

Andersson A, Isaksson A, Hultberg B . Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem. 1992; 38(7):1311-5. View

Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H . The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophr Res. 2013; 150(1):157-62. DOI: 10.1016/j.schres.2013.07.051. View

Vuksan-Cusa B, Sagud M, Jakovljevic M, Mihaljevic Peles A, Jaksic N, Mihaljevic S . Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry. 2012; 67(5):320-5. DOI: 10.3109/08039488.2012.745601. View

Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S . Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. 2014; 40(5):1154-63. PMC: 4133669. DOI: 10.1093/schbul/sbt154. View

Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt D . Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry. 2005; 162(9):1738-40. DOI: 10.1176/appi.ajp.162.9.1738. View

Roffman J, Brohawn D, Nitenson A, Macklin E, Smoller J, Goff D . Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull. 2011; 39(2):330-8. PMC: 3576161. DOI: 10.1093/schbul/sbr150. View

Applebaum J, Shimon H, Sela B, Belmaker R, Levine J . Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res. 2004; 38(4):413-6. DOI: 10.1016/j.jpsychires.2004.01.003. View

Lu M, Lin C, Chen Y, Yang H, Wu T . Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. PLoS One. 2013; 8(5):e65719. PMC: 3669135. DOI: 10.1371/journal.pone.0065719. View

Muntjewerff J, Kahn R, Blom H, den Heijer M . Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2005; 11(2):143-9. DOI: 10.1038/sj.mp.4001746. View

10.

Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A . 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374(9690):620-7. DOI: 10.1016/S0140-6736(09)60742-X. View

11.

van Winkel R, Rutten B, Peerbooms O, Peuskens J, van Os J, De Hert M . MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010; 121(1-3):193-8. DOI: 10.1016/j.schres.2010.05.030. View

12.

Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z . Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Lett. 2011; 32(2):141-7. View

13.

Hasnain M, Fredrickson S, Vieweg W, Pandurangi A . Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10(3):209-16. DOI: 10.1007/s11892-010-0112-8. View

14.

Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N . Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013; 210(3):825-9. DOI: 10.1016/j.psychres.2013.08.056. View

15.

Hill M, Shannahan K, Jasinski S, Macklin E, Raeke L, Roffman J . Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011; 127(1-3):41-5. DOI: 10.1016/j.schres.2010.12.006. View

16.

McGuffin P, Farmer A, Harvey I . A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991; 48(8):764-70. DOI: 10.1001/archpsyc.1991.01810320088015. View

17.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011; (1):CD006626. PMC: 4167865. DOI: 10.1002/14651858.CD006626.pub2. View

18.

Ellingrod V, Taylor S, Dalack G, Grove T, Bly M, Brook R . Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol. 2012; 32(2):261-5. PMC: 3622480. DOI: 10.1097/JCP.0b013e3182485888. View

19.

Garcia-Bueno B, Bioque M, Mac-Dowell K, Fe Barcones M, Martinez-Cengotitabengoa M, Pina-Camacho L . Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. 2013; 40(2):376-87. PMC: 3932081. DOI: 10.1093/schbul/sbt001. View

20.

Levine J, Stahl Z, Sela B, Gavendo S, Ruderman V, Belmaker R . Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry. 2002; 159(10):1790-2. DOI: 10.1176/appi.ajp.159.10.1790. View